Press Releases

Press Releases
Date Title and Summary View
Dec 7, 2017 -- Phase III Secondary Endpoint Results Demonstrate A Significantly Higher Disease-free Survival Rate following ABRAXANE as Investigational Therapy in Neoadjuvant Breast Cancer -- NEU-ISENBURG, Germany & SUMMIT, N.J.--(BUSINESS WIRE)-- The German Breast Group (GBG) and Celgene Corporation (N...
Dec 10, 2017 Overall response rate (ORR) of 94% in patients in active dose cohorts (doses above 50 x 106 CAR + T-cells) Complete Response (CR) rate of 56% observed in patients in active dose cohorts Median progression free survival (PFS) not reached with median follow up of 40 weeks in...
Dec 11, 2017 —74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in...
Dec 21, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported results from a phase III, randomized, open-label, international clinical study (RELEVANCE). This i...
Jan 2, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 36th Annual J.P. Morgan Healthcare Conference on January 8, 2018 at 10:30 a.m. ET, Celgene Corporation (NASDAQ: CELG) will present a business update on the Company in addition to preliminary unaudited 2017 financial results. The presentation and breakout session ...
Jan 3, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, January 25, 2018 at 9 a.m. ET to discuss fourth quarter and full-year 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celge...
Jan 7, 2018 Fedratinib is a highly selective JAK2 kinase inhibitor that is being evaluated for myelofibrosis and polycythemia vera Fedratinib demonstrated clinical improvement in a phase III trial with treatment-naïve myelofibrosis patients and in a phase II trial with myelofibrosis patients ...
Jan 8, 2018 - Preliminary Q4 2017 total revenue of $3.5 billion, a 17 percent increase Y/Y - Preliminary FY 2017 total revenue of $13.0 billion, a 16 percent increase Y/Y - Reaffirming 2020 total revenue and adjusted diluted EPS financial targets SUMMIT,...
Jan 19, 2018 Phase II LAPACT trial results reported on the safety and efficacy of ABRAXANE + gemcitabine induction therapy on tumor burden, disease control, and symptoms SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated resul...
Jan 22, 2018 Acquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene's Research and Operational Capabilities JCAR017 is Expected to be a Significant Growth Driver Beyond 2020 with Potential Global Peak Sales of Approximately $3B Reaffirming 2020 Fin...
FirstPrevious ...
46
... NextLast
Add to Briefcase = add release to Briefcase